Do VDR Gene Polymorphisms Contribute to Breast Cancer?
Fouzia Shaikh1, Saeeda Baig, Qamar Jamal
1Ziauddin University, Karachi, Pakistan
Asian Pacific Journal of Cancer Prevention : APJCP
|March 2, 2016
Summary
This study investigated vitamin D receptor (VDR) gene polymorphisms and their link to breast cancer risk. Despite exploring VDR gene variations, the research found no conclusive evidence to support a significant association with breast cancer development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Breast cancer is a leading global cancer in females.
- Vitamin D receptor (VDR) gene polymorphisms are studied for their potential role in breast cancer.
- Ethnic variations may influence the relationship between VDR gene and breast cancer.
Purpose of the Study:
- To assess and compare the impact of specific VDR gene polymorphisms (Fok1, Bsm1, Taq1, Apa1, poly (A)) on breast cancer development.
- To synthesize existing research on VDR gene polymorphisms and breast cancer risk.
Main Methods:
- A literature review was conducted using PubMed and Google Scholar.
- Search terms included "genetics", "breast cancer", "VDR gene", and "polymorphisms".
- Articles published between 1996 and 2015 were analyzed.
Main Results:
- Inconsistent results were found across studies.
- No definitive conclusions could be drawn regarding the significance of VDR genotypes in breast cancer development.
Conclusions:
- The current body of evidence does not conclusively link VDR gene polymorphisms to breast cancer development.
- Further research may be needed to clarify the role of VDR gene variations in breast cancer etiology.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:27Principles of Pharmacogenetics: Types of Genetic Variants
87
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
110
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
110
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
2.9K
2.9K